1.955

0.26% -0.005

Enveric Biosciences Inc (ENVB)

Overview News Price History Financials Discussions Forecast Stock Split Dividend History

Enveric Biosciences Inc stock is traded at $1.955, with a volume of 2,652. It is down -0.26% in the last 24 hours and down -1.76% over the past month. Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Previous Close:

$1.96

Open:

$1.97

24h Volume:

2,652

Relative Volume:

0.01

Market Cap:

$3.69M

Revenue:

Net Income/Loss:

$-8.77M

P/E Ratio:

-0.0711

EPS:

-27.4806

Net Cash Flow:

$-8.14M

1W Performance:

-3.69%

1M Performance:

-1.76%

6M Performance:

-76.88%

1Y Performance:

-86.54%

1-Day Range:

$1.94

$1.97

1-Week Range:

$1.859

$2.10

52-Week Range:

$1.75

$17.84

Enveric Biosciences Inc Stock (ENVB) Company Profile

Name

Enveric Biosciences Inc

Sector

Healthcare (1113)

Industry

Biotechnology (624)

Phone

(617) 444-8400

Address

245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2026-03-27

Latest SEC Filings

ENVB's Discussions on Twitter

Compare ENVB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENVB Enveric Biosciences Inc	1.955	3.70M	0	-8.77M	-8.14M	-27.48
VRTX Vertex Pharmaceuticals Inc	440.60	112.92B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	767.08	81.99B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	786.76	48.82B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	325.48	43.66B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	311.92	34.65B	5.36B	287.73M	924.18M	2.5229

Enveric Biosciences Inc Stock (ENVB) Latest News

Apr 07, 2026

Short Squeeze: Is Enveric Biosciences Inc a potential multi bagger2026 Spike Watch & Detailed Earnings Play Alerts - baoquankhu1.vn

Apr 07, 2026

Apr 04, 2026

If You Invested $1,000 in Enveric Biosciences Inc (ENVB) - Stock Titan

Apr 04, 2026

Apr 03, 2026

Enveric (ENVB) asks shareholders to OK 1-for-5–1-for-50 reverse split; raises authorized shares - Stock Titan

Apr 03, 2026

Apr 02, 2026

ENVB Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 02, 2026

Mar 31, 2026

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates - Investing News Network

Mar 31, 2026

ENVB Should I Buy - Intellectia AI

Mar 31, 2026

Enveric Biosciences Reports Q4 2025 Financial Results - Intellectia AI

Mar 31, 2026

Enveric Biosciences (ENVB) Secures U.S. Patent for EVM301 Series Molecules - GuruFocus

Mar 31, 2026

Enveric Biosciences Increceives U.S. patent for Evm301 series of drug candidates on March 17 - marketscreener.com

Mar 31, 2026

Enveric Biosciences receives U.S. patent for EVM301 molecules By Investing.com - Investing.com Canada

Mar 31, 2026

Mar 30, 2026

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 - marketscreener.com

Mar 30, 2026

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - National Today

Mar 30, 2026

Short Interest in Enveric Biosciences, Inc. (NASDAQ:ENVB) Drops By 20.6% - Defense World

Mar 30, 2026

Mar 28, 2026

Enveric Biosciences Reports 2025 Financial Results and Advances EB-003 Non-Hallucinogenic Neuroplastogen Toward Clinical Trials - Minichart

Mar 28, 2026

Enveric Biosciences: Advancing Non-Hallucinogenic Psychedelic Drug Development for Mental Health Disorders - Minichart

Mar 28, 2026

Mar 27, 2026